Company intelligence
MagVenture
Grounded in research, committed to treatment, focused on results: unlocking the science of TMS for treating depression.
About MagVenture
MagVenture® is a medical device manufacturer of world leading magnetic stimulation systems. From its headquarters in Denmark, MagVenture® develops and markets advanced medical equipment based on the use of pulsating magnetic fields for clinical examination as well as for research in the areas of psychiatry, neurophysiology, neurology, cognitive neuroscience, and rehabilitation. MagVenture’s product line MagPro® is designed especially for the needs of researchers and healthcare professionals. With 7 different magnetic stimulators and +30 different coils, the MagPro line provides a solution to most stimulation needs. MagVenture TMS Therapy® is CE approved for the treatment of Major Depressive Disorder, OCD and Addiction (PSUD). Furthermore, MagVenture TMS Therapy can reduce the symptoms of Comorbid Anxiety in patients suffering from depression. For the US: FDA cleared for treatment of Major Depressive Disorder - (Standard TMS) MagPro® stimulators R20, R30, R30 with MagOption, X100, and X100 with MagOption are all FDA 510(k) cleared for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode (k170114, k150641 and k171481). FDA cleared for treatment of Major Depressive Disorder – (Theta Burst) MagPro® stimulators R30 with theta burst option, X100 and X100 with MagOption are all FDA 510(k) cleared for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode (k173620) FDA cleared for adjunct treatment of Obsessive-Compulsive Disorder MagPro stimulators R30, R30 with MagOption, X100 and X100 with MagOption are all FDA 510 (k) cleared as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD) (k193006) For more information please visit www.magventure.com
Verified activity
Signals from MagVenture
6 published signals
Presence & Recognition
MagVenture held its International Sales Meeting 2026 at the headquarters in Denmark.
Reported by MagVenture
Presence & Recognition
MagVenture participated in Psych Congress 2026 in New Orleans, Louisiana, from September 15 to 19, 2026, to engage in Booth #1205.
Reported by MagVenture
Presence & Recognition
MagVenture announced that the 41st Annual Research Meeting will take place from October 7–9, 2026, with the theme Technologies for Care: Access, Innovation, and Recovery in Mental Health.
Reported by MagVenture
Presence & Recognition
MagVenture is hosting Day 1 of the International Sales Meeting 2026 in Denmark for 44 countries.
Reported by MagVenture
Presence & Recognition
MagVenture announced that Prof. Dr. Michael Landgrebe and Prof. Dr. Peter Zwanzger will lead a practice-focused session on October 2, 2026, in Nuremberg, Germany, covering rTMS, MEP determination, clinical applications, current standards, and reimbursement procedures.
Reported by MagVenture
Presence & Recognition
MagVenture announced that the Pre-RAI 2026 Course-Workshop: Non-Invasive Neuromodulation in Depression will be held in Mexico City on October 5, 2026, coordinated by Ruth Alcalá Lozano.
Reported by MagVenture